Where to buy 4-Fluoromethylphenidate (4F-MPH) for sale online

Summary

4-Fluoromethylphenidate, also known as 4-FMPH and 4F-MPH, is a stimulant substance known for its higher potency as a dopamine reuptake inhibitor compared to its closely related counterpart, methylphenidate.
Further scientific exploration delved into 4-Fluoromethylphenidate and other analogues of (±)-three-methylphenidate (TMP) with the aim of evaluating their potential as medications for countering cocaine addiction. In this research, 4F-MPH exhibited an ED50 of 0.26 mg/kg (with a range of 0.18–0.36 mg/kg), signifying its effectiveness as a substitute for cocaine. Additionally, it displayed a relative potency of 3.33 when compared to methylphenidate for the same purpose. This evaluation was based on its binding affinity to the dopamine transporter in relation to its performance as a dopamine reuptake inhibitor. The underlying idea is that 4F-MPH could potentially mitigate some of the effects of cocaine without being habit-forming.[5] It’s important to note that this concept has occasionally been misinterpreted as a measure of dopamine versus norepinephrine selectivity.
Another study inquired into the three-isomers of methylphenidate and found that compounds with electron-withdrawing substituents in meta- and para-positions tended to exhibit enhanced binding potency. Substances incorporating fluorine, chlorine, bromine, and methyl groups were reported to possess greater potency than methylphenidate, including its closely related compound, 4F-EPH. Specifically, 4F-MPH was found to have the following values: [3H]WIN 35428 binding of 35.0 ± 3.0 (2) and [3H]dopamine 142 ± 2.0 (2).

Identifiers

IUPAC name
CAS Number	1354631-33-6
PubChem CID	70876096
ChemSpider	26350585
UNII	TN2LV2C0X9
Chemical and physical data
Formula	C14H18FNO2
Molar mass	251.301 g·mol−1

Legal status

In the state of Alabama, USA, 4-fluoromethylphenidate is classified as a Schedule I controlled substance. Additionally, as of May 5, 2017, Canada has also designated 4-fluoromethylphenidate as a controlled substance.

FAQ

1. What is 4-Fluoromethylphenidate (4-FMPH)? 

4-Fluoromethylphenidate, often referred to as 4-FMPH, is a stimulant drug. It is known for its potent dopamine reuptake inhibition effects and is structurally related to methylphenidate.

2. How does 4-FMPH differ from methylphenidate? 

4-FMPH is considered to be more potent as a dopamine reuptake inhibitor compared to methylphenidate. This difference in potency can influence its effects and potential applications.

3. What is the potential use of 4-FMPH? 

4-FMPH has been studied for its potential as an anti-cocaine medication. It is believed to block some of the effects of cocaine without being as addictive. However, its use and research are subject to regulations in different countries.

4. Is 4-FMPH a controlled substance? 

Yes, 4-fluoromethylphenidate is classified as a controlled substance in certain regions and countries. For example, it is a Schedule I controlled substance in the U.S. state of Alabama and is controlled in Canada.

5. What are the legal regulations surrounding 4-FMPH? 

The legal status of 4-FMPH varies by country and region. It is essential to be aware of and comply with local laws and regulations regarding the possession, use, and distribution of this substance.

6. What are the potential risks and side effects of 4-FMPH use? 

As a stimulant, 4-FMPH use may come with various risks and side effects. These can include cardiovascular issues, mental health disturbances, and the potential for addiction. Detailed information should be sought from reliable sources and healthcare professionals.

7. Can 4-FMPH be detected in drug tests? 

Yes, 4-fluoromethylphenidate can potentially be detected in drug tests, depending on the specific tests used and the duration since its last use.

8. Is there any legitimate medical use for 4-FMPH? 

As of my last knowledge update in September 2021, there were limited or no recognized medical applications for 4-FMPH. Its research was primarily focused on potential anti-cocaine medication properties. Always consult with healthcare professionals for the most up-to-date information on any substance.

References

1. “The Drug Enforcement Administration’s Special Testing and Research Laboratory Monograph” (PDF): This document, dated February 2017, likely contains information and research findings related to controlled substances and their properties.
2. Davies HM, Hopper DW, Hansen T, Liu Q, Childers SR (April 2004): In this April 2004 research publication, the synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites are explored.
3. Misra M, Shi Q, Ye X, Gruszecka-Kowalik E, Bu W, Liu Z, et al. (October 2010): This October 2010 study delves into quantitative structure-activity relationship studies of threo-methylphenidate analogs, offering insights into their properties and potential applications.
4. Singh S (March 2000): In March 2000, this research publication discusses the chemistry, design, and structure-activity relationship of cocaine antagonists, shedding light on compounds that interact with cocaine.
5. Schweri MM, Deutsch HM, Massey AT, Holtzman SG (May 2002): This May 2002 research publication presents a biochemical and behavioral characterization of novel methylphenidate analogs, providing valuable data on their effects and potential uses.
6. Deutsch HM, Shi Q, Gruszecka-Kowalik E, Schweri MM (March 1996): In March 1996, this study explores the synthesis and pharmacology of potential cocaine antagonists, specifically examining the structure-activity relationship of aromatic ring-substituted methylphenidate analogs.
7. “Alabama Senate Bill 333 – Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am’d” (March 2014): This legislative bill from March 2014 pertains to controlled substances in Alabama, including the inclusion of synthetic controlled substances and analogues in Schedule I.
8. “Regulations Amending the Food and Drug Regulations (Part G — Methylphenidate)” (April 5, 2017): Dated April 5, 2017, this document from Health Canada discusses amendments to the Food and Drug Regulations related to methylphenidate, likely addressing its regulation and control in Canada.